Viking Therapeutics, Inc (VKTX)
Health Care ยท Pharmaceutical Preparations
Viking Therapeutics, Inc (VKTX) is listed on Nasdaq, where its shares have traded since April 29, 2015. SentiSense covers Viking Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Brian Lian is its chief executive officer. The company reports 74 employees, and its corporate website is www.vikingtherapeutics.com.
About Viking Therapeutics, Inc
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Latest reported results
Viking Therapeutics, Inc. reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended September 30, 2026, 323 institutions reported holding VKTX, with 58.4 million shares worth $1.9 billion in aggregate. The largest reported holders were Vanguard, FMR and BlackRock. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on VKTX
- VKTX sentiment: whether news and social coverage of Viking Therapeutics, Inc leans bullish or bearish, and the stories driving it.
- VKTX ownership: all 323 reporting institutions, plus insider and congressional trades.
- VKTX financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Viking Therapeutics, Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Viking Therapeutics, Inc do?
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders.
What sector is VKTX in?
SentiSense classifies Viking Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does VKTX stock trade?
Viking Therapeutics, Inc (VKTX) is listed on Nasdaq, where its shares have traded since April 29, 2015.
Who is the CEO of Viking Therapeutics, Inc?
Brian Lian is the chief executive officer of Viking Therapeutics, Inc.